Search

Your search keyword '"Zecca,Chiara"' showing total 172 results

Search Constraints

Start Over You searched for: Author "Zecca,Chiara" Remove constraint Author: "Zecca,Chiara" Database Unpaywall Remove constraint Database: Unpaywall
172 results on '"Zecca,Chiara"'

Search Results

1. Irisin Levels in Cerebrospinal Fluid Correlate with Biomarkers and Clinical Dementia Scores in Alzheimer Disease

2. Effectiveness, Safety and Patients’ Satisfaction of Nabiximols (Sativex®) on Multiple Sclerosis Spasticity and Related Symptoms in a Swiss Multicenter Study

5. Patterns of a structural covariance network associated with Mild Behavioural Impairment in biologically defined Alzheimer’s Disease

6. Visual migraine aura iconography: A multicentre, cross-sectional study of individuals with migraine with aura

9. Besonderheiten der Immuntherapie der Multiplen Sklerose in der Schweiz: Update

10. Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS

11. Biometry extraction and probabilistic anatomical atlas of the anterior Visual Pathway using dedicated high-resolution 3-D MRI

12. Cohort analysis of novel SPAST variants in SPG4 patients and implementation of in vitro and in vivo studies to identify the pathogenic mechanism caused by splicing mutations

13. Self-reports by persons with multiple sclerosis are an adequate surrogate for healthcare provider data on disease-modifying therapy and multiple sclerosis type

14. Phase I clinical trial of intracerebroventricular transplantation of allogeneic neural stem cells in people with progressive multiple sclerosis

16. Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study

19. Short-Term Irisin Treatment Enhanced Neurotrophin Expression Differently in the Hippocampus and the Prefrontal Cortex of Young Mice

20. Incidence of syndromes associated with Frontotemporal Lobar Degeneration (S19.004)

21. Serum Glial Fibrillary Acidic Protein compared with Neurofilament Light Chain as Biomarker for Multiple Sclerosis Disease Progression (P5-3.016)

23. Once-Daily Subcutaneous Irisin Administration Mitigates Depression- and Anxiety-like Behavior in Young Mice

25. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis

26. Prevalence and Burden of Migraine in Switzerland: Cross-Sectional Study in ten Specialised Headache Centres from the BECOME Study

27. Synthesizing cross‐design evidence and cross‐format data using network meta‐regression

29. Engagement in volunteering activities by persons with multiple sclerosis in Switzerland

31. Correlation of disability with quality of life in patients with multiple sclerosis treated with natalizumab: primary results and post hoc analysis of the TYSabri ImPROvement study (PROTYS)

32. Specific Aspects of Immunotherapy for Multiple Sclerosis in Switzerland—A Structured Commentary, Update 2022

34. Correction: Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results

35. Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results

36. Longitudinal Postvaccine SARS-CoV-2 Immunoglobulin G Titers, Memory B-Cell Responses, and Risk of COVID-19 in Multiple Sclerosis Over 1 Year

37. The Real-World Experiences of Persons With Multiple Sclerosis During the First COVID-19 Lockdown: Application of Natural Language Processing

38. Association of age and disease duration with comorbidities and disability: A study of the Swiss Multiple Sclerosis Registry

39. Feelings of loneliness, COVID-19-specific-health anxiety and depressive symptoms during the first COVID-19 wave in Swiss persons with multiple sclerosis

40. Spinal cord lesions and brain grey matter atrophy independently predict clinical worsening in definite multiple sclerosis: a 5-year, multicentre study

43. Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis

44. A CLEIA Antigen Assay in Diagnosis and Follow-Up of SARS-CoV-2-Positive Subjects

47. Decipher non‐canonicalSPASTsplicing mutations with the help of functional assays in patients affected by spastic paraplegia 4 ( SPG4 )

50. Spinal Cord Lesions and Brain Grey Matter Atrophy Independently Predict Clinical Worsening in Multiple Sclerosis: A 5-Year, Multicentre Study (P16-4.004)

Catalog

Books, media, physical & digital resources